Live feed08:00:00·578dPRReleasevia QuantisnowScience 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease TrialByQuantisnow·Wall Street's wire, on your screen.SNCE· Science 37 Holdings Inc.Technology
